Background: Information and communication technologies (ICTs) improve patient-centered care and are routinely used in Allergic Rhinitis (AR), but patients’ preferences and attitudes are unexplored. This study examines AR-related information preferences and ICT use by AR patients. Methods: A survey-based cross-sectional study was carried out in Ecuador in seven centers of reference of allergic disease. Participants were 18 or older, diagnosed with AR, and had access to ICT and the internet. Descriptive and binomial logistic regression were done. A value of less than 0.05 was considered statistically significant. Results: 217 patients were included. 47% used ICTs to learn about AR, 38.2% found it useful. 75% disagreed that ICTs reduce doctor’s appointments. Individuals with poorer quality of life were 27% more likely to utilize ICTs to contact their doctor and 23% more likely to be interested in AR-related content. Patients with long-term AR or other allergies were less likely to use ICTs. Higher education and lower quality of life may increase AR app adoption by 4.8 times. Academic preparation five-fold increased ICT use for health provider communication. Mild-persistent allergic rhinitis 12 times enhanced the probabilities of using ICTs to share experiences and communicate with other patients. Conclusions: Our study found that moderate-to-severe AR individuals are not interested in information despite ICTs’ potential benefits. Consequently, allergists should use evidence-based resources and establish new technological options for content, follow-up, and emotional support for AR patients in Ecuador.

Coronavirus disease 2019 (COVID-19) vaccine BNT162b2 received approval and within the first few days of public vaccination several severe anaphylaxis cases occurred. An investigation is taking place to understand the cases and their triggers. The vaccine will be administered to a large number of individuals worldwide and concerns raised for severe adverse events might occur. With the current information, the European Academy of Allergy and Clinical Immunology (EAACI) states its position for the following preliminary recommendations that are to be revised as soon as more data emerges. To minimize the risk of severe allergic reactions in vaccinated individuals, it is urgently required to understand the specific nature of the reported severe allergic reactions, including the background medical history of the individuals affected and the mechanisms involved. To achieve this goal all clinical and laboratory information should be collected and reported. Mild and moderate allergic patients should not be excluded from the vaccine as the exclusion of all these patients from vaccination may have a significant impact on reaching the goal of population immunity. Health care practitioners vaccinating against COVID-19 are required to be sufficiently prepared to recognise and treat anaphylaxis properly with the ability to administer adrenaline. A mandatory observation period after vaccine administration of at least 15 minutes for all individuals should be followed. The current guidelines, which exclude patients with severe allergies from vaccination with BNT162b2, should be re-evaluated after more information and experience with the new vaccine develops.